The drug Wegovy uses an active ingredient called Semaglutide which is part of a growing class of GLP-1 drugs that make people feel full, reducing their calorie intake.
Anti-obesity jabs could reduce the risk of heart attacks, strokes or heart failure in obese people regardless of the amount of weight they lose while on the drug, researchers have found. The largest and longest study of the obesity drug Wegovy has also shown people maintain significant weight loss for at least four years, with fewer serious adverse events than those given placebo 'dummy' treatment.
None of them had diabetes, but all had previously had a heart attack, stroke or peripheral artery disease. Over the first two years of the study, the proportion of people who were obese fell sharply from 71% to 43% in the group given Wegovy. But in those given placebo injections, the rate dropped only slightly, from 72% to 68%.
United Kingdom Latest News, United Kingdom Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Semaglutide improves heart failure symptoms and reduces loop diuretic doseSemaglutide reduces the need for loop diuretic use and dose, and has positive effects on symptoms, physical limitations, and body weight in patients with heart failure with preserved ejection fraction (HFpEF) regardless of diuretic use, according to late breaking research presented today at Heart Failure 2024, a scientific congress of the European...
Read more »
Endoscopic sleeve gastroplasty is cost saving versus semaglutide, finds studyFor individuals with class II obesity, endoscopic sleeve gastroplasty (ESG) is cost saving compared with semaglutide, according to a study published online April 12 in JAMA Network Open.
Read more »
Semaglutide alleviates metabolic-linked liver disease in people with HIVFor people with HIV (PWH), semaglutide is effective for metabolic dysfunction-associated steatotic liver disease (MASLD), according to a research letter published online April 30 in the Annals of Internal Medicine.
Read more »
New rules mean 3.6 million Americans could get Wegovy via Medicare, costing billionsA budget-busting 3.6 million Medicare recipients could now be eligible for coverage of the weight-loss drug Wegovy, a new KFF analysis says.
Read more »
Obesity drug shows significant weight loss for at least four years, with fewer serious events, study findsThe drug, Wegovy, uses an active ingredient called Semaglutide which is part of a growing class of GLP-1 drugs that make people feel full, reducing their calorie intake.
Read more »
Anti-obesity jab ‘cuts risk of heart attack or stroke regardless of weight lost’A weekly dose of Wegovy, alongside standard care for the prevention of heart attacks or stroke, lowered the risk by 20% compared with those given a placebo.
Read more »